Русский
Goflikicept: a new promising drug for the treatment of recurrent pericarditis
DOI: https://dx.doi.org/10.18565/pharmateca.2025.6.30-34
Vydashenko A.V., Elagin D.V., Sheremet M.I.
Order of the Red Banner of Labor Institute named after S.I. Georgievsky, Simferopol, Russia
Recurrent idiopathic pericarditis is an autoimmune inflammatory disease of the pericardium characterized by repeated episodes of inflammation after 4–6 weeks of remission. This article examines the historical development and current understanding of the pathogenesis of recurrent pericarditis as an interleukin-1 (IL-1)-dependent autoinflammatory disease. It describes the efficacy of targeted therapy compared to standard treatments and the advantages of goflikicept, the first and only Russian drug, compared to other IL-1 antagonists. The paper also examines the results of a study of its safety profile and efficacy during long-term therapy.
Keywords: IL-1 antagonists, recurrent idiopathic pericarditis, goflikicept, autoinflammation, pericarditis
About the Autors
D.V. Elagin, Student, Order of the Red Banner of Labor Institute named after S.I. Georgievsky, Simferopol, Russia; denis.elagin@vk.com,
ORCID: https://orcid.org/0009-0006-6252-0636, eLibrary SPIN: 2546-8230 (corresponding author)
A.V. Vydashenko, Order of the Red Banner of Labor Institute named after S.I. Georgievsky, Simferopol, Russia; ORCID: https://orcid.org/0000-0002-0351-8185
M.I. Sheremet, Order of the Red Banner of Labor Institute named after S.I. Georgievsky, Simferopol, Russia; ORCID: https://orcid.org/0009-0003-2011-0805
